title: NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.
abstract: A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.
authors.affiliation: Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia.
authors.forename: Igor
authors.initials: I
authors.lastname: Bakulin
authors.affiliation: Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia.
authors.forename: Victor
authors.initials: V
authors.lastname: Pasechnikov
authors.affiliation: Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia.
authors.forename: Anna
authors.initials: A
authors.lastname: Varlamicheva
authors.affiliation: Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia.
authors.forename: Irina
authors.initials: I
authors.lastname: Sannikova
keywords: Adverse event; Antiviral treatment; Hepatitis C virus; PEGylated interferon-α; Protease inhibitor; Response-guided therapy; Ribavirin